|
Neuroblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A<sub>2A</sub> Rs modulate STEP activity also in the SH-SY5Y neuroblastoma cell line, where a calcium-dependent calcineurin/PP1 pathway was found to play a major role.
|
31520531 |
2020 |
|
Central neuroblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A<sub>2A</sub> Rs modulate STEP activity also in the SH-SY5Y neuroblastoma cell line, where a calcium-dependent calcineurin/PP1 pathway was found to play a major role.
|
31520531 |
2020 |
|
Childhood Neuroblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A<sub>2A</sub> Rs modulate STEP activity also in the SH-SY5Y neuroblastoma cell line, where a calcium-dependent calcineurin/PP1 pathway was found to play a major role.
|
31520531 |
2020 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.010 |
Biomarker
|
disease |
BEFREE |
Artefactual inflation of type 2 diabetes prevalence in WHO STEP surveys.
|
30706604 |
2019 |
|
Short Bowel Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Retracing our STEPs: Four decades of progress in intestinal lengthening procedures for short bowel syndrome.
|
30514435 |
2019 |
|
Sepsis-Associated Encephalopathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
In summary, our results support the key role of STEP in sepsis-induced memory impairment in a mouse model of SAE, whereas inhibition of STEP may provide a novel therapeutic approach for this disorder and possible other neurodegenerative diseases.
|
31691882 |
2019 |
|
Osteoarthritis, Knee
|
0.010 |
Biomarker
|
disease |
BEFREE |
This trial will provide information on the effectiveness of STEP-KOA as a novel potential model of care for treatment of OA.
|
31138256 |
2019 |
|
Pain in spine
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Loss of STEP61 couples disinhibition to N-methyl-d-aspartate receptor potentiation in rodent and human spinal pain processing.
|
31135041 |
2019 |
|
Neurodegenerative Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
In summary, our results support the key role of STEP in sepsis-induced memory impairment in a mouse model of SAE, whereas inhibition of STEP may provide a novel therapeutic approach for this disorder and possible other neurodegenerative diseases.
|
31691882 |
2019 |
|
Tumor Initiation
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Targeting the pyrimidine synthetic rate-limiting step enzyme carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, dihydroorotase (CAD) or the critical downstream enzyme dihydroorotate dehydrogenase (DHODH) inhibited GSC survival, self-renewal, and in vivo tumor initiation through the depletion of the pyrimidine nucleotide supply in rodent models.
|
31391321 |
2019 |
|
alcohol effect
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
These data suggest that stress history reduces the aversive properties of moderate alcohol doses, and that alcohol aversion is associated with acute alcohol effects on pCREB and STEP expression in the extended amygdala.
|
30336151 |
2019 |
|
Idiopathic Pulmonary Fibrosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Exploratory analyses of the STEP-IPF (Sildenafil Trial of Exercise Performance in IPF) trial suggested that sildenafil may have a greater effect on SGRQ score in patients with IPF who have right heart dysfunction (RHD).<b>Objectives:</b> Assess whether RHD influenced the effects of nintedanib plus sildenafil versus nintedanib alone in the INSTAGE trial.<b>Methods:</b> Subgroup analyses of patients with (<i>n</i> = 117) versus those without (<i>n</i> = 156) echocardiographic signs of RHD at baseline.<b>Measurements and Main Results:</b> There was no heterogeneity between subgroups by presence of RHD in the effect of nintedanib plus sildenafil versus nintedanib alone on change in SGRQ total score at Week 12 (<i>P</i> = 0.74) or Week 24 (<i>P</i> = 0.90), or change in FVC at Week 12 (<i>P</i> = 0.58) or Week 24 (<i>P</i> = 0.55).
|
31365829 |
2019 |
|
Mental disorders
|
0.010 |
AlteredExpression
|
group |
BEFREE |
STriatal-Enriched protein tyrosine Phosphatase (STEP) is a neural-specific protein that opposes the development of synaptic strengthening and whose levels are altered in several neurodegenerative and psychiatric disorders.
|
30760987 |
2018 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
Further, PTPN5 expression is strongly associated with good clinical outcome in tamoxifen treated human breast cancer patients suggesting that PTPN5 may represent a novel biomarker of tamoxifen response in human breast cancer.
|
29590203 |
2018 |
|
Cognition Disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
We found that genetic deletion of STEP delayed the onset of motor dysfunction and prevented the appearance of cognitive deficits in R6/1 mice.
|
30176350 |
2018 |
|
Mental Depression
|
0.010 |
Biomarker
|
disease |
BEFREE |
Earlier we showed that striatal-enriched protein tyrosine phosphatase (STEP) inhibitor - 8-(trifluoromethyl)-1,2,3,4,5-benzopentathiepin-6-amine hydrochloride (TC-2153) affects both the brain serotoninergic system and the brain-derived neurotropic factor that are known to be involved in the psychopathology of depression.
|
30367948 |
2018 |
|
Depressive disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Earlier we showed that striatal-enriched protein tyrosine phosphatase (STEP) inhibitor - 8-(trifluoromethyl)-1,2,3,4,5-benzopentathiepin-6-amine hydrochloride (TC-2153) affects both the brain serotoninergic system and the brain-derived neurotropic factor that are known to be involved in the psychopathology of depression.
|
30367948 |
2018 |
|
Fatigue
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Provision of pedometers, with and without providing step targets, was successful in increasing activity levels and decreasing fatigue in this sample of individuals with RA.
|
28378441 |
2018 |
|
Fragile X Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
These studies suggest that STEP inhibition may have therapeutic benefit in FXS.
|
28943283 |
2018 |
|
Hypertensive disease
|
0.010 |
Biomarker
|
group |
BEFREE |
Burden of hypertension in The Gambia: evidence from a national World Health Organization (WHO) STEP survey.
|
29394353 |
2018 |
|
Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
We show that Ptpn5 is a novel tamoxifen regulated target gene which is upregulated in MECs after transient tamoxifen exposure and displays tumor suppressor activity in human breast cancer cells.
|
29590203 |
2018 |
|
Abnormal behavior
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
STriatal-Enriched protein tyrosine Phosphatase (STEP) is a neural-specific protein that opposes the development of synaptic strengthening and whose levels are altered in several neurodegenerative and psychiatric disorders.
|
30760987 |
2018 |
|
Impaired cognition
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We found that genetic deletion of STEP delayed the onset of motor dysfunction and prevented the appearance of cognitive deficits in R6/1 mice.
|
30176350 |
2018 |
|
Depressed mood
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Earlier we showed that striatal-enriched protein tyrosine phosphatase (STEP) inhibitor - 8-(trifluoromethyl)-1,2,3,4,5-benzopentathiepin-6-amine hydrochloride (TC-2153) affects both the brain serotoninergic system and the brain-derived neurotropic factor that are known to be involved in the psychopathology of depression.
|
30367948 |
2018 |
|
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Further, PTPN5 expression is strongly associated with good clinical outcome in tamoxifen treated human breast cancer patients suggesting that PTPN5 may represent a novel biomarker of tamoxifen response in human breast cancer.
|
29590203 |
2018 |